Targeting Splicing in the Treatment of Human Disease

dc.contributor.authorSuñé Pou, Marc
dc.contributor.authorPrieto-Sánchez, Silvia
dc.contributor.authorBoyero-Corral, Sofía
dc.contributor.authorMoreno Castro, Cristina
dc.contributor.authorEl Yousfi, Younes
dc.contributor.authorSuñé i Negre, Josep M. (Josep Maria)
dc.contributor.authorHernández-Munain, Cristina
dc.contributor.authorSuñé, Carlos
dc.date.accessioned2021-02-16T12:38:05Z
dc.date.available2021-02-16T12:38:05Z
dc.date.issued2017
dc.date.updated2021-02-16T12:38:06Z
dc.description.abstractThe tightly regulated process of precursor messenger RNA (pre-mRNA) alternative splicing (AS) is a key mechanism in the regulation of gene expression. Defects in this regulatory process affect cellular functions and are the cause of many human diseases. Recent advances in our understanding of splicing regulation have led to the development of new tools for manipulating splicing for therapeutic purposes. Several tools, including antisense oligonucleotides and trans-splicing, have been developed to target and alter splicing to correct misregulated gene expression or to modulate transcript isoform levels. At present, deregulated AS is recognized as an important area for therapeutic intervention. Here, we summarize the major hallmarks of the splicing process, the clinical implications that arise from alterations in this process, and the current tools that can be used to deliver, target, and correct deficiencies of this key pre-mRNA processing event. Keywords: alternative splicing, precursor messenger RNA, therapy, genetic disease
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec668376
dc.identifier.issn2073-4425
dc.identifier.pmid28245575
dc.identifier.urihttps://hdl.handle.net/2445/173991
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/genes8030087
dc.relation.ispartofGenes, 2017, vol. 8, num. 87, p. 1-17
dc.relation.urihttps://doi.org/10.3390/genes8030087
dc.rightscc-by (c) Suñé Pou, Marc et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationNanopartícules
dc.subject.classificationTeràpia genètica
dc.subject.classificationMalalties hereditàries
dc.subject.classificationNanotecnologia
dc.subject.otherNanoparticles
dc.subject.otherGene therapy
dc.subject.otherGenetic diseases
dc.subject.otherNanotechnology
dc.titleTargeting Splicing in the Treatment of Human Disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
668376.pdf
Mida:
1.66 MB
Format:
Adobe Portable Document Format